Ichor Holdings
ICHR
$95.03
+6.32%
Ichor Holdings designs, engineers, and manufactures critical fluid delivery subsystems and components primarily for semiconductor capital equipment, with additional applications in defense/aerospace and medical industries. The company operates as a key supplier within the semiconductor equipment ecosystem, providing essential subsystems for processes like etch and electroplating. The current investor narrative is overwhelmingly driven by a powerful cyclical recovery in the semiconductor capital equipment sector, with the stock's extraordinary year-to-date price surge reflecting expectations of a sharp rebound in demand from foundry and logic customers. This has positioned Ichor as a high-beta play on the semiconductor cycle, with recent trading activity suggesting intense speculation on the timing and magnitude of the industry upturn.…
ICHR
Ichor Holdings
$95.03
Investment Opinion: Should I buy ICHR Today?
Rating: Hold. The core thesis is that while ICHR is a compelling, high-beta play on a semiconductor equipment recovery, its current valuation after a 465% rally and lack of profitability warrant caution, making it suitable only for risk-tolerant investors with a high conviction in the near-term cycle.
Supporting Evidence: The stock trades at a seemingly reasonable PS ratio of 0.68x, but the forward P/E of 37.74x is demanding. Analyst estimates project a dramatic earnings recovery to $3.87 EPS, but this is from a single source. The balance sheet is a positive with low debt (D/E 0.28), but profitability metrics are negative (Net Margin -5.57%). The technical picture shows extreme momentum but also extreme volatility (beta 1.884) and overbought conditions.
Risks & Conditions: The two biggest risks are 1) failure to achieve the forecasted profitability, invalidating the forward P/E, and 2) a sharp technical correction following its parabolic rise. This Hold rating would upgrade to Buy on a significant pullback (e.g., towards the $65 support zone) that improves the risk/reward profile, or on confirmation of margin expansion and EPS acceleration in upcoming quarterly reports. It would downgrade to Sell if the company reports continued losses or guides below the $3.87 EPS target, or if the stock breaks below key technical support on high volume. The stock is currently overvalued based on trailing fundamentals but could be fairly valued if the aggressive forward estimates are met.
Sign up to view all
ICHR 12-Month Price Forecast
The outlook for ICHR is a binary bet on the semiconductor equipment cycle. The neutral stance reflects the high probability base case where the company executes but the stock's massive rally has likely front-run much of the near-term good news. Confidence is medium due to the lack of recent quarterly financial data and minimal analyst coverage, which obscures the current trajectory. The key is whether the company can translate the anticipated cyclical demand into actual margin expansion and profits. The stance would turn bullish on confirmation of sustained margin improvement and order strength in upcoming reports. It would turn bearish if the next earnings release shows continued losses or deteriorating cash flow, proving the rally was speculative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Ichor Holdings's 12-month outlook, with a consensus price target around $123.54 and implied upside of +30.0% versus the current price.
Average Target
$123.54
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$76 - $124
Analyst target range
Analyst coverage for Ichor Holdings appears extremely limited, with data indicating only one analyst providing estimates. This suggests the stock has minimal institutional research coverage, which is typical for smaller-cap names within the semiconductor supply chain and can lead to higher volatility and less efficient price discovery due to lower information transparency. The single analyst estimates revenue of approximately $2.01 billion and EPS of $3.87 for the forward period, but no consensus price target, recommendation, or target range is available in the provided data; the lack of a target price and the absence of a Buy/Hold/Sell distribution means there is no clear analyst-derived upside/downside signal, placing greater emphasis on investors' own interpretation of the cyclical fundamentals and technical picture.
Bulls vs Bears: ICHR Investment Factors
The evidence currently tilts bearish on a risk-adjusted basis, despite the powerful bullish momentum. The bear case is anchored in concrete, current financial weakness—unprofitability and razor-thin margins—coupled with an extreme, speculative price surge that appears disconnected from present fundamentals. The bull case is entirely forward-looking, predicated on a flawless cyclical recovery and perfect execution to bridge the massive gap between negative trailing earnings and a lofty forward P/E of 37.74x. The single most important tension in the investment debate is the timing and magnitude of ICHR's profitability recovery. If the company delivers on the forecasted $3.87 EPS, the bull thesis validates the current price. If margin improvement is slower than expected or the cycle falters, the stock's elevated valuation and technical overextension present substantial downside risk.
Bullish
- Explosive Price Momentum: The stock has surged 464.78% over the past year and 110.57% over the past three months, dramatically outperforming the SPY's 15.14% gain. This reflects intense market anticipation of a powerful cyclical recovery in the semiconductor capital equipment sector, with ICHR positioned as a high-beta beneficiary.
- Strong Balance Sheet & Liquidity: The company maintains a conservative debt-to-equity ratio of 0.28 and a robust current ratio of 3.16. This low leverage and high liquidity provide a solid financial foundation to navigate the cycle and potentially fund operations without distress, mitigating near-term solvency risks.
- Analyst Forecasts Robust Profit Recovery: The single analyst covering ICHR forecasts a forward EPS of $3.87, implying a dramatic swing from the current trailing EPS of -$0.08. This forward P/E of 37.74x, while high, is predicated on the company returning to significant profitability as the industry upturn materializes.
- Attractive Price-to-Sales Multiple: The stock trades at a trailing PS ratio of 0.68x, which appears low for a company tied to a high-growth, capital-intensive industry. This suggests the market may not be fully pricing in the potential revenue acceleration from the semiconductor equipment cycle, offering a potential valuation cushion.
Bearish
- Current Unprofitability & Thin Margins: ICHR is currently operating at a loss with a trailing net margin of -5.57% and an EPS of -$0.08. Its gross margin of 9.26% is exceptionally thin, indicating significant cost pressures or competitive pricing in its manufacturing niche, raising questions about its path to sustainable profitability.
- Extreme Volatility & Overextended Rally: With a beta of 1.884, the stock is 88% more volatile than the market. Trading at 99% of its 52-week high after a parabolic +52.69% 1-month gain, the technical picture suggests the rally is overextended and highly vulnerable to a sharp correction or profit-taking, as evidenced by a recent -40.8% max drawdown.
- Valuation Gap Relies on Perfect Execution: The market is valuing the stock at a forward P/E of 37.74x based on estimated future profits, a stark contrast to its negative trailing earnings. This creates a massive valuation gap that depends entirely on the company hitting aggressive analyst EPS targets of $3.87, leaving no room for execution missteps or a delayed recovery.
- Minimal Analyst Coverage & Transparency: The stock has coverage from only one analyst, with no consensus price target or recommendation available. This lack of institutional research leads to lower information transparency and less efficient price discovery, potentially amplifying volatility and making fundamental assessment more difficult for investors.
ICHR Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +464.78%. As of the latest close at $98.61, the price is trading at approximately 99% of its 52-week high of $99.6, indicating extreme momentum and positioning the stock at the absolute peak of its recent range, which suggests both strong bullish conviction and a heightened risk of a technical pullback or consolidation. Recent short-term momentum is exceptionally strong but shows signs of volatility, with a 1-month gain of +52.69% and a 3-month gain of +110.57%, significantly outpacing the broader market's 0.74% and 15.14% gains over the same periods; this divergence from the SPY highlights Ichor's role as a high-beta cyclical stock, but the explosive 1-month move may also signal an overextended condition ripe for profit-taking. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $99.6 and support likely forming around the recent pullback low near $62.91; a decisive breakout above $100 could signal a new phase of the rally, while a breakdown below the $65 support zone would suggest a deeper correction. The stock's beta of 1.884 confirms it is approximately 88% more volatile than the market, a critical factor for risk management given its parabolic ascent.
Beta
1.88
1.88x market volatility
Max Drawdown
-40.8%
Largest decline past year
52-Week Range
$13-$102
Price range past year
Annual Return
+404.9%
Cumulative gain past year
| Period | ICHR Return | S&P 500 |
|---|---|---|
| 1m | +30.7% | -2.2% |
| 3m | +110.1% | +15.8% |
| 6m | +401.5% | +6.4% |
| 1y | +404.9% | +20.9% |
| ytd | +365.6% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ICHR Fundamental Analysis
Revenue and growth trajectory data from the most recent quarter is not available in the provided dataset, preventing a direct analysis of top-line trends, segment performance, or acceleration/deceleration. The company's profitability is currently under pressure, with a trailing net margin of -5.57% and an EPS of -$0.08, indicating it is operating at a loss; the gross margin of 9.26% and operating margin of -4.14% are thin, suggesting significant cost pressures or competitive pricing in its subsystem manufacturing business, though without sequential quarterly data, the margin trend (expanding or compressing) cannot be determined. The balance sheet appears conservatively leveraged with a debt-to-equity ratio of 0.28, indicating a low reliance on debt financing, and a strong current ratio of 3.16 points to robust short-term liquidity; however, key cash flow metrics like Free Cash Flow are unavailable, making it difficult to assess the company's ability to fund operations internally versus relying on external capital.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ICHR Overvalued?
Given the negative trailing Net Income and EPS, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.68x and an Enterprise Value-to-Sales (EV/Sales) of 3.18x; the forward PE of 37.74x, based on estimated EPS, suggests the market is pricing in a significant return to profitability and strong future earnings growth, creating a large valuation gap between the negative trailing earnings and optimistic forward expectations. Peer comparison data for industry average multiples is not provided, so a relative valuation assessment against the semiconductor equipment sector cannot be performed. Historical valuation context is also unavailable due to missing historical ratios data, preventing an analysis of whether the current PS or EV/Sales multiples are at the high or low end of the stock's own historical range, which is a significant gap in determining if the stock is priced for perfection or offers relative value.
PE
-12.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-98.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is the company's current lack of profitability, with a trailing net margin of -5.57% and an operating margin of -4.14%. The gross margin of 9.26% is alarmingly thin for a manufacturing business, indicating severe pricing pressure or high input costs that could impede a return to positive earnings. While the balance sheet is strong (D/E of 0.28), the business is currently a cash consumer (negative EPS), and without current cash flow data, its ability to internally fund operations through a prolonged downturn is uncertain. The valuation is entirely dependent on a forecasted sharp earnings rebound, creating binary execution risk.
Market & Competitive Risks: The stock's extreme beta of 1.884 makes it highly sensitive to broader market and sector sentiment. Trading at a forward P/E of 37.74x amidst current losses, it is priced for perfection regarding the semiconductor equipment cycle. Any disappointment in the timing or strength of the industry recovery, or a sector-wide de-rating of growth multiples, could trigger severe multiple compression. As a subsystem supplier, ICHR also faces competitive and pricing pressure from larger equipment OEMs and peers, which could constrain the margin recovery implied in its forward estimates.
Worst-Case Scenario: The worst-case involves a delay or cancellation of the anticipated semiconductor capex recovery, combined with persistent margin pressure. This would lead to the company missing its forward EPS target of $3.87, revealing the forward P/E as unjustified and causing a rapid re-rating towards its tangible book value or sales multiple. Given the stock's volatility and recent 40.8% max drawdown, a retracement to its 52-week low of $13.12 is unlikely in the near term, but a 35-50% correction from the current ~$98 level to the recent support zone near $62.91 is a realistic adverse scenario, representing a potential loss of over one-third of capital.
FAQ
The key risks are, in order of severity: 1) Execution Risk: The company must dramatically improve its -5.57% net margin to hit forward EPS targets; failure would collapse the valuation thesis. 2) Cyclical Timing Risk: The stock is a pure play on semiconductor capex; a delay or downturn in the equipment cycle would severely impact sales. 3) Volatility Risk: With a beta of 1.884, the stock is prone to wild swings, and its 465% rally increases the risk of a sharp, painful correction (recent max drawdown was -40.8%). 4) Information Risk: Minimal analyst coverage (only one) reduces transparency and can lead to inefficient price discovery, amplifying other risks.
Based on a probabilistic framework, the 12-month forecast includes three scenarios. The Base Case (50% probability) sees the stock trading between $75 and $95 as the cyclical recovery proceeds and the company meets the analyst's $3.87 EPS estimate. The Bull Case (25% probability) targets $110-$130 on a stronger-than-expected cycle and earnings beat. The Bear Case (25% probability) warns of a drop to $50-$65 if the recovery stalls and profitability fails to materialize. The most likely scenario is the Base Case, which assumes the forecasted earnings recovery is achieved but that the stock's massive rally limits further multiple expansion in the near term.
ICHR presents a paradox: it appears undervalued on a Price-to-Sales basis (PS 0.68x) but is arguably overvalued on an earnings basis. The trailing P/E is negative due to losses, while the forward P/E of 37.74x is steep and entirely dependent on forecasted profits materializing. Compared to its own book value (P/B ~0.98), it is roughly fairly valued. The valuation implies the market is paying a significant premium for future growth that has not yet appeared in the financial statements. Therefore, it is overvalued relative to its current fundamentals but could be fairly valued if the aggressive forward estimates are achieved.
ICHR is a high-risk, high-potential-reward stock that may be a good buy only for a specific investor profile. After a 465% year-to-date surge, the easy money has likely been made, and the stock is priced for a perfect recovery (forward P/E 37.74x). For aggressive traders with a high tolerance for volatility (beta 1.884) and a firm belief that the semiconductor equipment cycle is accelerating, any significant pullback could present an entry point. However, for most investors, it is not a good buy at current levels due to its lack of current profitability, thin margins, and extreme technical overextension. The investment hinges entirely on the company hitting a single analyst's $3.87 EPS target.
ICHR is primarily suitable for medium-term tactical investing aligned with the semiconductor equipment cycle, not for long-term buy-and-hold. Its high beta (1.884), lack of dividend, and cyclical nature make it a poor fit for long-term stability. The investment thesis is centered on a specific 12-24 month recovery window. Given the extreme volatility and the need to monitor quarterly execution against the $3.87 EPS target, a minimum holding period of 6-12 months is suggested to see the story play out, but investors must be prepared to act on changes in fundamental data. It is generally unsuitable for short-term trading except for very experienced traders due to its erratic price movements.